BroadOak Capital Partners Invests Growth Capital in PhenoVista Biosciences

BroadOak Capital Partners and RCT Invest in Biolog, Inc.

May 12, 2022

Biotechnology

BroadOak Capital Partners and Research Corporation Technologies (RCT) made a growth capital investment in Biolog, Inc., a Hayward, California-based provider of cell-based microbial identification and phenotypic profiling technologies. As part of the recapitalization, Robert Wicke was named CEO and the company will use proceeds to advance its cellular analysis product portfolio and expand commercial adoption across pharmaceutical, academic, biotech and environmental markets.

BroadOak Capital Partners Makes $2.0M Growth Investment in KromaTiD

April 28, 2021

Biotechnology

BroadOak Capital Partners provided $2.0 million of growth capital to KromaTiD to accelerate commercialization, support product development (including dGH In-Site and dGH SCREEN) and expand capacity to meet rising demand. KromaTiD, a Longmont, Colorado-based provider of single-cell genomic structural analysis for gene editing and gene therapy applications, will use the funding to grow its services and product offerings to biopharma and research customers.

Oakley Capital Acquires Majority Stake in vitroconnect

May 14, 2024

Telecommunications

Oakley Capital's Origin II fund has agreed to acquire a majority stake in vitroconnect, a German broadband open access platform based in Gütersloh. The founder and management team will remain involved, and Oakley will support the company as it scales to capture growth from Germany's accelerating FTTH rollout.

Avista Capital Partners Acquires Taconic Biosciences

November 1, 2022

Biotechnology

Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.

Axol Bioscience Acquires Phenocell

October 21, 2024

Biotechnology

Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.

Vista Equity Partners Provides Minority Growth Investment in Benchmark Gensuite

April 25, 2023

Cloud & SaaS

Benchmark Gensuite, a Cincinnati/Mason-based provider of EHS, Sustainability and ESG reporting software, received a minority growth investment from Vista Equity Partners' Endeavor Fund. The undisclosed investment — Vista will take a board seat — will be used to accelerate product development, deepen customer partnerships, and expand the company's market reach.